Rechallenge with cetuximab (cet) plus irinotecan (iri) in 3rd-line in RAS and BRAF wt metastatic colorectal cancer (mCRC) patients (pts) with acquired resistance to 1st-line cet plus iri: the phase II CRICKET study by GONO
Journal article published in 2017 by
D. Santini,
C. Cremolini,
L. Salvatore 
,
S. Lonardi,
E. Dell'Aquila,
M. Cattaneo,
F. Loupakis,
D. Rossini,
B. Vincenzi,
S. Ziampiri,
Buoro,
E. Tamburini,
D. Basile,
D. C. Corsi,
I. Fioroni
and other authors.
,
S. Lonardi,
E. Dell'Aquila,
M. Cattaneo,
F. Loupakis,
D. Rossini,
B. Vincenzi,
S. Ziampiri,
Buoro,
E. Tamburini,
D. Basile,
D. C. Corsi,
I. Fioroni
and other authors.
